Competitive Technologies (CTT) Receives $1 Million Sales Order From Excel Life Sciences
More News related to CTT
- Competitive Technologies Commercially Launches Pain Management Medical Device in U.S.
- ACT and 37 Small Tech Firms Urge FTC to Proceed With Caution on Intel
- Competitive Tech. (CTT) Posts Q1 Loss of 8c, Better Y/Y
- Competitive Technologies Reports First Quarter Fiscal 2010 Results
- Competitive Tech (CTT) Establishes Joint Distributorship with Hospital Consulting SpA
More News related to Corporate News
- S&P Announces Change to US Index: TSRA for FIF
- RealNetworks (RNWK) and MTV Networks (VIA-B) to Split Off Joint Venture Rhapsody
- Watts Water (WTS) Board Approves Restructuring Program; Shutting Down 3 Plants, Cutting 95 Jobs
- Transcept Pharmaceuticals (TSPT) Granted U.S. Patent Covering Intermezzo Formulation
- AAR (AIR) Predicts Impact of Mesa's Bankruptcy on Q3 Results
Competitive Technologies, Inc. (NYSE: CTT) has received a sales order from Excel Life Sciences, Inc. (ELS) for pain management therapy devices. The device is a non-invasive method for rapid treatment of high-intensity oncologic and neuropathic pain, including pain resistant to morphine and other drugs. ELS, CTT's country-exclusive distributor in India, recognizing the benefits of the innovative device, was the first announced healthcare services provider to sign a distribution agreement for the device. Subsequent distribution agreements granted country-exclusive distribution rights to GEOMC Co., Ltd. for Korea, to AG Healthcare for Malaysia, and to Biogene Pharma Limited for Bangladesh.
The order from ELS has an approximate retail value of up to $1 million. Shipment of the devices to ELS is scheduled to begin immediately.
Competitive Technologies, established in 1968, provides distribution, patent and technology transfer, sales and licensing services focused on the needs of its customers and matching those requirements with commercially viable product or technology solutions.[SM]
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
